<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2014-12-65-69</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-690</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTERIAL HYPERTENSION</subject></subj-group></article-categories><title-group><article-title>Индивидуальный выбор дезагреганта для длительной терапии больных ишемической болезнью сердца: обоснование и реализация</article-title><trans-title-group xml:lang="en"><trans-title>Patient-specific choice of an antiplatelet drug for long-term therapy of coronary heart disease: rationale and implementationL</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мазур</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mazur</surname><given-names>NA</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия последипломного образования Минздрава России, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Postgraduate Education, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2014</year></pub-date><volume>0</volume><issue>12</issue><fpage>65</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мазур Н.А., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Мазур Н.А.</copyright-holder><copyright-holder xml:lang="en">Mazur N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/690">https://www.med-sovet.pro/jour/article/view/690</self-uri><abstract><p>Во всех урбанизированных странах более половины всех летальных исходов связано с болезнями, обусловленными атеротромбозом артерий сердца, мозга. В России, по сравнению со странами Европы и США, показатель смертности в 3-5 раз выше. Наиболее важными мероприятиями, обеспечившими на протяжении последних 15-20 лет во многих странах снижение смертности, кроме популяризации среди всего населения здорового образа жизни, здорового питания, явилось также широкое использование дезагрегантов для профилактики атеротромбоза в группе высокого риска его возникновения, а также лечение с их помощью заболевших. Вместе с тем среди населения с низким риском возникновения ишемической болезни сердца, ишемической болезни мозга терапия аспирином не приводила к снижению кардиоваскулярной летальности, что было установлено при наблюдении за 95 тыс. лиц с низким риском в течение в среднем 6,9 года [<xref ref-type="bibr" rid="cit1">1</xref>].</p></abstract><trans-abstract xml:lang="en"><p>In all urbanized countries, more than half of overall mortality is conditioned by diseases caused by atherothrombosis in the arteries of heart and brain. In Russia, as compared with Europe and the United States, the mortality rate is 3-5 times higher. The key factors that in many countries contributed to a reduction in mortality over the past 15-20 years, in addition to overall popularization of a healthy lifestyle and healthy diet, was the widespread use of antiplatelets for the prevention and treatment of atherothrombotic events in high-risk groups. However, in populations with low risks of coronary artery disease and brain ischemia, aspirin therapy did not result in a decrease in cardiovascular mortality, which was confirmed by a follow-up of 95,000 patients at low risk for an average period of 6.9 years. [<xref ref-type="bibr" rid="cit1">1</xref>]</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антиагригантная терапия</kwd><kwd>плагрил</kwd><kwd>клопидогрел</kwd><kwd>ацетилсалициловая кислота</kwd><kwd>antiplatelet therapy</kwd><kwd>plagril</kwd><kwd>clopidogrel</kwd><kwd>acetylsalicylic acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373: 1849-1860.</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373: 1849-1860.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133: 199-233.</mixed-citation><mixed-citation xml:lang="en">Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133: 199-233.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">CAPRIE Steering Committtee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-1339.</mixed-citation><mixed-citation xml:lang="en">CAPRIE Steering Committtee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-1339.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002, 12, 324 (7329): 71-86.</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002, 12, 324 (7329): 71-86.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST elevation. NEJM 2005, 352: 1179-1189.</mixed-citation><mixed-citation xml:lang="en">CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST elevation. NEJM 2005, 352: 1179-1189.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y-H, Wei X, Lu J et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outtcomes: a systematic review and meta-analysis. wwwplosone.org. 2012, 7, 2.</mixed-citation><mixed-citation xml:lang="en">Zhou Y-H, Wei X, Lu J et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outtcomes: a systematic review and meta-analysis. wwwplosone.org. 2012, 7, 2.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
